Haemonetics Net Worth
Haemonetics Net Worth Breakdown | HAE |
Haemonetics Net Worth Analysis
Haemonetics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Haemonetics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Haemonetics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Haemonetics' net worth analysis. One common approach is to calculate Haemonetics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Haemonetics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Haemonetics' net worth. This approach calculates the present value of Haemonetics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Haemonetics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Haemonetics' net worth. This involves comparing Haemonetics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Haemonetics' net worth relative to its peers.
Enterprise Value |
|
To determine if Haemonetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Haemonetics' net worth research are outlined below:
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: The five-year underlying earnings growth at Haemonetics is promising, but the shareholders are still in the red over that time |
Haemonetics Quarterly Good Will |
|
Haemonetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Haemonetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Haemonetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 9th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Know Haemonetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Haemonetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Haemonetics backward and forwards among themselves. Haemonetics' institutional investor refers to the entity that pools money to purchase Haemonetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royal Bank Of Canada | 2025-03-31 | 1.1 M | Dimensional Fund Advisors, Inc. | 2025-03-31 | 1.1 M | Allspring Global Investments Holdings, Llc | 2025-03-31 | 966.2 K | Schroder Investment Management Group | 2025-03-31 | 965.2 K | Fmr Inc | 2025-03-31 | 843.3 K | Fisher Asset Management, Llc | 2025-03-31 | 734.5 K | Sg Capital Management, Llc | 2025-03-31 | 719.4 K | Northern Trust Corp | 2025-03-31 | 651.4 K | Marshall Wace Asset Management Ltd | 2025-03-31 | 648.6 K | Blackrock Inc | 2025-03-31 | 6.4 M | Vanguard Group Inc | 2025-03-31 | 5.1 M |
Follow Haemonetics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 3.53 B.Market Cap |
|
Project Haemonetics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.12 | 0.05 | |
| Return On Capital Employed | 0.12 | 0.07 | |
| Return On Assets | 0.07 | 0.04 | |
| Return On Equity | 0.20 | 0.06 |
When accessing Haemonetics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Haemonetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Haemonetics' profitability and make more informed investment decisions.
Please note, the presentation of Haemonetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Haemonetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Haemonetics' management manipulating its earnings.
Evaluate Haemonetics' management efficiency
Haemonetics has Return on Asset of 0.0665 % which means that on every $100 spent on assets, it made $0.0665 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1883 %, implying that it generated $0.1883 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. As of July 19, 2025, Return On Tangible Assets is expected to decline to 0.05. In addition to that, Return On Capital Employed is expected to decline to 0.07. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 981.7 M, whereas Other Current Assets are forecasted to decline to about 56.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.31 | 14.26 | |
| Tangible Book Value Per Share | (4.75) | 7.29 | |
| Enterprise Value Over EBITDA | 14.32 | 25.70 | |
| Price Book Value Ratio | 3.87 | 5.13 | |
| Enterprise Value Multiple | 14.32 | 25.70 | |
| Price Fair Value | 3.87 | 5.13 | |
| Enterprise Value | 1.4 B | 1.5 B |
Evaluating the management effectiveness of Haemonetics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Haemonetics Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 3.3089 | Revenue | Quarterly Revenue Growth (0.04) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Haemonetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Haemonetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Haemonetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Haemonetics Corporate Filings
| 13th of June 2025 Other Reports | ViewVerify | |
F4 | 9th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 6th of June 2025 Other Reports | ViewVerify | |
| 27th of May 2025 Other Reports | ViewVerify |
Haemonetics Earnings per Share Projection vs Actual
Haemonetics Corporate Directors
| Robert Abernathy | Independent Director | Profile | |
| Claire Pomeroy | Independent Director | Profile | |
| Catherine Burzik | Independent Director | Profile | |
| Mark Kroll | Independent Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.946 | Earnings Share 3.31 | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.